Developments in NON-CYSTIC FIBROSIS BRONCHIECTASIS: From Diagnosis to Novel Mechanisms Addressing Neutrophilic Inflammation
This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians
Tuesday, October 8, 2024
6:00 AM – 7:30 AM ET simulcast
5:00 AM – 6:30 AM CT
4:00 AM – 5:30 AM MT
3:00 AM – 4:30 AM PT
1.5 CME/CNE Credits
Features:
- Online personalized quality-improvement poster-generation portal
Learning Objectives
- Analyze factors contributing to the pathophysiology of non-CF bronchiectasis to better understand the mechanism of action of emerging therapies that target neutrophil serine proteases
- Evaluate best practices in the diagnosis of non-CF bronchiectasis
- Summarize best practices in managing neutrophilic inflammation in non-CF bronchiectasis
- Discuss the results of clinical trials on approved and novel therapies for non-CF bronchiectasis that target neutrophil serine proteases
Target Audience
This activity is designed to meet the educational needs of US-based health care providers, clinicians, and researchers who have a role in the diagnosis and treatment of patients with non-CF bronchiectasis who work in pulmonology, respiratory, and primary care.
Joint Accreditation Statement
Physician Credit Designation Statement
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
Nurses (ANCC) Credit Designation
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure Of Unlabeled Use
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Release date: October 8, 2024
Expiration date: October 8, 2024
Estimated time to completion: 1.5 hours
